Advertisement
Canada markets closed
  • S&P/TSX

    22,308.93
    -66.90 (-0.30%)
     
  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     
  • DOW

    39,512.84
    +125.08 (+0.32%)
     
  • CAD/USD

    0.7317
    +0.0006 (+0.08%)
     
  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     
  • Bitcoin CAD

    83,388.02
    -2,644.17 (-3.07%)
     
  • CMC Crypto 200

    1,260.45
    -97.56 (-7.18%)
     
  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     
  • RUSSELL 2000

    2,059.78
    -13.85 (-0.67%)
     
  • 10-Yr Bond

    4.5040
    +0.0550 (+1.24%)
     
  • NASDAQ

    16,340.87
    -5.40 (-0.03%)
     
  • VOLATILITY

    12.55
    -0.14 (-1.10%)
     
  • FTSE

    8,433.76
    +52.41 (+0.63%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • CAD/EUR

    0.6789
    +0.0011 (+0.16%)
     

Analyst Recommendations for Herbalife before 4Q17

Analyst Recommendations for Herbalife before 4Q17

Of the analysts covering Herbalife (HLF) stock, 50% of them are recommending a “buy,” and 50% are recommending a “hold.” Herbalife’s sales and profitability were subdued in the first three quarters of 2017. Herbalife’s financials are expected to remain challenged in the near term, given the weakness in its key regions. Currently, analysts have a price target of $86.80 per share for Herbalife stock, which represents an upside of 3.5% compared to its closing price of $83.88 on February 15, 2018.